IMMUNOTHERAPY
Clinical trials for IMMUNOTHERAPY explained in plain language.
Never miss a new study
Get alerted when new IMMUNOTHERAPY trials appear
Sign up with your email to follow new studies for IMMUNOTHERAPY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple-Threat attack on tough liver cancer shows promise
Disease control OngoingThis study is looking at a three-part treatment for people with intermediate to advanced liver cancer who cannot have surgery. It combines a procedure to cut off the tumor's blood supply and deliver chemo, followed by precise radiation and a drug that helps the immune system figh…
Matched conditions: IMMUNOTHERAPY
Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New combo attack on tough esophageal cancer
Disease control OngoingThis study is testing a three-part treatment for people with advanced esophageal cancer who cannot have surgery. First, patients receive immunotherapy plus chemotherapy, followed by a combination of chemotherapy and radiation. The goal is to see if this approach helps control the…
Matched conditions: IMMUNOTHERAPY
Phase: PHASE2 • Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New combo therapy aims to shrink tumors before esophageal cancer surgery
Disease control OngoingThis study is testing if adding an immunotherapy drug (camrelizumab) to standard radiation helps shrink tumors before surgery for esophageal cancer. It will involve 25 patients with operable esophageal squamous cell carcinoma. The main goals are to see if this combination is safe…
Matched conditions: IMMUNOTHERAPY
Phase: PHASE1, PHASE2 • Sponsor: Fujian Medical University Union Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New combo attack on tough sarcomas before surgery
Disease control OngoingThis study is testing a new treatment approach for patients with certain soft tissue sarcomas. Before surgery, patients receive a combination of two immunotherapy drugs and a course of radiation therapy. The main goal is to see how much of the tumor is killed by this pre-surgery …
Matched conditions: IMMUNOTHERAPY
Phase: PHASE2 • Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Nanoparticle 'Booster' trial aims to supercharge cancer treatment
Disease control OngoingThis early-stage trial is testing whether injecting a nanoparticle called NBTXR3 directly into a tumor, then activating it with radiation, can make immunotherapy work better for people with advanced cancers. The study will enroll about 145 patients with various cancers that have …
Matched conditions: IMMUNOTHERAPY
Phase: PHASE1 • Sponsor: Nanobiotix • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New hope to slow advanced prostate cancer
Disease control OngoingThis study is testing whether adding a new immunotherapy drug called lorigerlimab to standard chemotherapy (docetaxel) can help men with advanced prostate cancer live longer without their cancer getting worse. About 150 men whose cancer has spread and stopped responding to hormon…
Matched conditions: IMMUNOTHERAPY
Phase: PHASE2 • Sponsor: MacroGenics • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
New 'Double-Action' drug tested to shrink lung tumors before surgery
Disease control OngoingThis study is testing a new drug called Ivonescimab for people with non-small cell lung cancer who need surgery. It compares this new drug, which works by blocking two different cancer pathways at once, to standard immunotherapy drugs. The main goal is to see if the new drug is b…
Matched conditions: IMMUNOTHERAPY
Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Mar 13, 2026 15:05 UTC
-
Scientists hunt for bacterial clues to personalize lung cancer care
Knowledge-focused OngoingThis study aims to learn if the collection of bacteria in a patient's body (the microbiome) can help predict who will benefit from a specific lung cancer immunotherapy drug called durvalumab, or who might experience severe side effects. Researchers will collect stool, throat swab…
Matched conditions: IMMUNOTHERAPY
Sponsor: Leiden University Medical Center • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:40 UTC